SPECIALTY QUANTITY LIMIT PROGRAM

VITRAKVI (larotrectinib)

I. PROGRAM DESCRIPTION


The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Vitrakvi 25 mg capsules	180 per 30 days	 Adult dosing: 100 mg twice daily Pediatric dosing: 100 mg/m², not to exceed 100 mg, twice daily Dose modifications for adverse reactions and drug interactions: dose reduction by 25% to 75% may be required.
Vitrakvi 100 mg capsules	60 per 30 days	
Vitrakvi oral solution (20 mg/mL) 100 mL bottle	300 mL (3 bottles) per 30 days	

III. REFERENCES

1. Vitrakvi [package insert]. Stamford, CT: Loxo Oncology, Inc.; July 2019.



pharmaceutical manufacturers that are not affiliated with CVS Caremark.

© 2019 CVS Caremark. All rights reserved.





This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains prescription brand name drugs that are trademarks or registered trademarks of